What's Happening?
Contract development and manufacturing organizations (CDMOs) are facing a persistent capacity crunch as demand for biopharmaceutical manufacturing services continues to rise. According to BioPlan’s 23rd Annual Survey, nearly half of biopharma companies
report difficulties in finding CDMOs with available capacity for mammalian production. The challenges are particularly acute in advanced biotherapeutic areas like gene and cell therapy. The regionalization of biologics manufacturing is intensifying competition among CDMOs to deliver cost-effective, high-quality biologics at scale. Smaller start-up biologics companies are increasingly reliant on CDMOs due to a lack of facilities and expertise.
Why It's Important?
The capacity constraints in the CDMO sector highlight the growing demand for biopharmaceutical manufacturing services, driven by the expansion of biologics and advanced therapies. This situation underscores the need for strategic investments in manufacturing capacity and technology adoption to meet industry demands. The constraints also reflect broader trends in the biopharma industry, such as the shift towards more complex biologics and the need for specialized manufacturing capabilities. Addressing these challenges is crucial for ensuring the timely delivery of innovative therapies to the market.
What's Next?
CDMOs are expected to continue expanding their capacity to meet the growing demand, with many projecting significant growth over the next five years. The industry is likely to see increased investment in new facilities and technologies to enhance manufacturing capabilities. Biopharma companies may also explore strategic partnerships and collaborations to secure the necessary manufacturing capacity. The ongoing capacity challenges may drive further innovation and operational transformation within the CDMO sector.
